FundedIQ
Biotechnology

Aukera Therapeutics: Funding, Investors & Team (Sep 2026)

Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein-related diseases such as cancer and neurogenerative diseases. Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel.

www.aukera-tx.com LinkedIn Basel, Switzerland 1-10 employees
Total raised
$5.6M
Rounds
1
Latest
Seed
Dec 2025

Aukera Therapeutics has raised $5.6M across 1 funding round on record, the most recent a Seed of $5.6M announced in Dec 2025.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Aukera Therapeutics Company Profile and Key Stats

Total funding raised
$5.6M
across 1 round on record
Funding rounds on record
1
Latest funding round
Seed
$5.6M in Dec 2025
Employees
1-10
reported band
Headquarters
Basel, Switzerland

Latest funding round on record: Dec 2025.

Aukera Therapeutics Funding Rounds

Date
Round
Amount
Seed
$5.6M

Aukera Therapeutics Founders and Leadership Team

Name
Role
Contact
Driton Liko
Founder

No contact details are on record for this team yet.

Aukera Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
879
$3.8M
16,485
$3.1M

Aukera Therapeutics' latest round of $5.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Aukera Therapeutics in Biotechnology and Basel

Companies Similar to Aukera Therapeutics

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…

Series A $40.0M

At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…

Pre-Seed $3.0M

compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…

Undisclosed round $1.2M

MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…

Undisclosed round $200M

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…

Undisclosed round $490k

Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…

Pre-Seed $120k

Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…

Undisclosed round $1.1M

AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…

Undisclosed round $4.0M

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…

Undisclosed round $1.2M

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…

Undisclosed round $1.4M

MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…

Undisclosed round $10.2M

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…

Seed $7.5M

Aukera Therapeutics Funding FAQs

What does Aukera Therapeutics do?

Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein-related diseases such as cancer and neurogenerative diseases. Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel.

How much funding has Aukera Therapeutics raised?

Aukera Therapeutics has raised $5.6M across 1 round on record. The most recent is a Seed of $5.6M announced in Dec 2025.

When did Aukera Therapeutics last raise funding?

Aukera Therapeutics' most recent funding round on record is a Seed of $5.6M, announced in Dec 2025.

Who founded Aukera Therapeutics?

FundedIQ lists Driton Liko (Founder) at Aukera Therapeutics.

Where is Aukera Therapeutics headquartered?

Aukera Therapeutics is based in Basel, Basel-Stadt, Switzerland.

How many employees does Aukera Therapeutics have?

Aukera Therapeutics is in the 1-10 employee band.

How does Aukera Therapeutics' funding compare to other Biotechnology startups?

Aukera Therapeutics' latest round of $5.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Aukera Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aukera Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.